Cannabis Law Report

NOVEMBER 16, 2021

Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging. Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). It’s everywhere. An anti-seizure wonder drug.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” . School: Tufts University.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Puff Puff Post

JANUARY 1, 2020

As a result, medical usage now grows substantially now that doctors and hospitals have access to legal cannabis. Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Nabiximols (known as “Sativex” outside US) in the US: Commence pivotal clinical program in initial target indication of spasticity associated with Multiple Sclerosis. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Puff Puff Post

JANUARY 1, 2020

As a result, medical usage now grows substantially now that doctors and hospitals have access to legal cannabis. Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. Nabiximol is a cannnabis derived drug that exited clinical trials in Spain.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Prior to joining Sesen Bio, Mr. Barbera served as the Vice President of Market Access at UroGen Pharma and played a critical role in the launch of the company’s first commercial product, Jelmyto ®. Julie Hoff to Vice President, Human Resources.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

JULY 12, 2019

As reported in the Guardian, Analytical Cannabis emphasises the importance of this for those suffering from conditions such as chronic pain, epilepsy and neurological and psychiatric disorders who have long been seeking access to what they hope is a transformative medicine.

Epilepsy 40

Epilepsy Medicine Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 1, 2021

The presentation can be accessed by registering (at no cost) for the Investor Forum at www.channelchek.com ; the investor portal created by Noble. Eastern time. The video webcast will be later archived on Channelchek as part of its C-Suite Series www.channelchek.com/c-suite , and on its YouTube channel. www.youtube.com/channelchek.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

SMPL

MAY 26, 2020

In the absence of oversight, the push to get more patients access to cannabis medicine — and bona fide CBD — has been co-opted by a push to make as much money as possible off the next big wellness fad. “At Alas, Mr. Gardner wrote in 2005, that would require access to expensive testing equipment. And because of public demand, the F.D.A.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

The Cannigma

DECEMBER 22, 2021

Listen & Subscribe: Israel is world-renowned for the research and innovation that is taking place there, and unofficial data suggests that around 20% of the Israeli population uses cannabis. The Cannabis Enigma is a co-production of The Cannigma and Americans for Safe Access. We have autism and epilepsy. Music by Desca.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40